Dr. Reddy's Laboratories Ltd.'s rituximab, a biosimilar version of Roche's monoclonal antibody MabThera/Rituxan, has made significant inroads in markets like India and Ukraine; approvals are also in place in Venezuela and Russia - all eyes are on a Russian tender for the product anticipated in November this year.
Dr Reddy's executive vice president and head branded markets (India and emerging countries), M V Ramana, said that the product...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?